German company Biotronik has launched Intica DX and Intica cardiac resynchronisation therapy (CRT)-DX implantable cardioverter defibrillator (ICD) systems in the US.
Following approval from the US Food and Drug Administration (FDA), the launch is intended to provide heart failure patients with the firm’s DX technology.
Go deeper with GlobalData
Originally introduced in 2013, DX eliminates the requirement for an atrial lead and delivers diagnostic information based on a true atrial signal to aid monitoring, management and prevention of cardiac events.
Intica CRT-DX is a cardiac rhythm management device designed to provide atrial diagnostics to enable early supraventricular tachycardia (SVT), atrial fibrillation (AF), and atrial ventricular synchronisation detection.
Biotronik president Marlou Janssen said: “Our DX technology is stand alone in an industry that knows the rate of complication increases with more leads. Doctors trust and rely on our DX technology because it delivers less hardware, less complication, and paramount diagnostics.
“We know that the impact of DX is profound for patients and that is why we invested in bringing Intica CRT-DX to market.”
Intica CRT-DX features the firm’s new MultiPole Pacing (MPP) technology developed to allow heart failure therapy customisation by sequentially or simultaneously pacing left ventricle (LV) twice per cardiac cycle.
The device also includes MRI AutoDetect to eliminate post-MRI reprogramming and shorten reduced therapy window, Biotronik Home Monitoring to automatically transmit device data, and closed loop stimulation for providing an accurate response to physiologic demands and acute mental stress.
With operations in more than 100 countries, Biotronik develops medical technologies for cardiovascular and endovascular applications.
Image: Biotronik’s Intica CRT-DX for heart failure patients. Photo: courtesy of PRNewsfoto/Biotronik.
